Shannon N Westin
M.D. Anderson Cancer Center · NRG Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
13
all conditions, ClinicalTrials.gov
NIH grants tied to them
3
NIH RePORTER
Trial papers
39
PubMed author-name match
Trials
Studies that name Shannon N Westin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:25 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07318324 · Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerM.D. Anderson Cancer Center · recruiting · Phase IB, Avutometinib, RAS Pathway · principal investigator
- Ph2NCT05554328 · Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialNational Cancer Institute (NCI) · active not recruiting · Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma · principal investigator
- N/ANCT04604613 · Prediction of Recurrence Among Low Risk Endometrial Cancer PatientsM.D. Anderson Cancer Center · active not recruiting · FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma · principal investigator
- Ph3NCT04269200 · Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial CancerAstraZeneca · active not recruiting · Endometrial Neoplasms · principal investigator
- Early Ph1NCT03943173 · Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before SurgeryM.D. Anderson Cancer Center · active not recruiting · BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation · principal investigator
- Ph1NCT03586661 · Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube CancerM.D. Anderson Cancer Center · completed · Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma · principal investigator
- Ph1/Ph2NCT02726997 · Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)M.D. Anderson Cancer Center · active not recruiting · Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7 · principal investigator
- Ph2NCT02684227 · Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial CancerM.D. Anderson Cancer Center · completed · Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7 · principal investigator
- Early Ph1NCT02659241 · Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal CancerM.D. Anderson Cancer Center · active not recruiting · Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma · principal investigator
- Ph2NCT02397083 · Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial CancerM.D. Anderson Cancer Center · active not recruiting · Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma · principal investigator
- Ph1NCT02208375 · mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianM.D. Anderson Cancer Center · active not recruiting · BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma · principal investigator
- Ph1NCT01935973 · Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial CancerNational Cancer Institute (NCI) · completed · Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma · principal investigator
- Ph2NCT00788671 · Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial CancerM.D. Anderson Cancer Center · active not recruiting · Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7, Stage IA Uterine Corpus Cancer AJCC v7 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $476,200 awarded in 2026Same name and institution; not confirmed by an ID
- Protocol Review and Monitoring SystemP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $344,069 awarded in 2026Same name and institution; not confirmed by an ID
- Targeting p300 to Overcome PARP inhibitor resistance induced by acidic tumor microenvironmentP50CA281701 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 · $341,501 awarded in 2023Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NRG Oncology Network Group Operations CenterU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2014 to 2026Named on NCT05554328, NCT01935973
- MD Anderson Gynecologic SPORE for Uterine CancersP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI RUSSELL R BROADDUS, Karen Hsieh Lu · fiscal years 2003 to 2020
- The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ROBERT C BAST · fiscal years 1999 to 2015Named on NCT02208375
- Gynecologic Oncology GroupU10CA027469 · NCI · GYNECOLOGIC ONCOLOGY GROUP · PI Philip J. DiSaia · fiscal years 1985 to 2013Named on NCT01935973
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:25 UTC. The ranking covers the 200 most relevant of 39 PubMed records, and a shared surname and initials can bring in a namesake. All 39 on PubMed
- A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).J Clin Oncol · 2022371 citationsRCR 24.8
- 344 citationsRCR 41.4
- Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.J Clin Oncol · 2018276 citationsRCR 12.2
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.Lancet Oncol · 2019218 citationsRCR 7.4
- 181 citationsRCR 5.4
- A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.Clin Cancer Res · 2018136 citationsRCR 4.4
- Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study.J Clin Oncol · 2020104 citationsRCR 5.0
- Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.Am J Obstet Gynecol · 2021103 citationsRCR 6.9
- Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.J Clin Oncol · 202398 citationsRCR 7.1
- 90 citationsRCR 4.3